Several ongoing trials demonstrate that CPI-613 (devimistat) is a potential treatment for pancreatic cancer, clear cell sarcoma, and biliary tract cancer.
Researchers at the University of California San Diego and La Jolla Institute of Immunology have discovered a promising treatment approach for pancreatic cancer, one of the deadliest and most treatment-resistant forms of cancer. The approach leverages the body’s natural immune response to cytomegalovirus, a common but typically harmless virus that most people are infected with at some point in their lives.
